A Free-for-All From Readers and Tweeters, From Medical Debt to Homelessness
KHN gives readers a chance to comment on a recent batch of stories.
Drugs
361 - 380 of 1,299 Results
-
-
KHN鈥檚 鈥榃hat the Health?鈥: Life After 鈥楻oe鈥 Is … Confusing
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Patients With Epilepsy Navigate Murky Unregulated CBD Industry
The FDA has approved a cannabis-derived drug, Epidiolex, to treat some forms of epilepsy. Now people who have other forms of the condition are using over-the-counter CBD products in hopes of taming their seizures. But doctors and patients worry about the unregulated world of CBD, in which product ingredients can be a mystery.
By Eric Berger -
Seeking to Kick-Start Biden鈥檚 Agenda, Schumer Unveils a Bill for Medicare Drug Price Negotiations
In addition to allowing federal officials to negotiate the price that Medicare pays for some drugs, the bill would cap annual out-of-pocket drug costs for Medicare beneficiaries at $2,000. But before Democrats can pass the bill under special rules that prevent Republicans from staging a filibuster, they must get approval from the Senate parliamentarian.
-
‘Free’ Screening? Know Your Rights to Get No-Cost Care
Even a decade in, the Affordable Care Act鈥檚 recommendations to simply cover preventive screening and care without cost sharing remain confusing and complex.
-
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government鈥檚 covid-fighting strategy.
By Arthur Allen -
Readers and Tweeters Weigh In on Medical Debt, the Obesity Epidemic, and Opioid Battles
KHN gives readers a chance to comment on a recent batch of stories.
-
KHN鈥檚 鈥榃hat the Health?鈥: The FDA Goes After Nicotine
The FDA is using its power to regulate tobacco products 鈥 ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN鈥檚 Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.
-
New Weight Loss Treatment Is Marked by Heavy Marketing and Modest Results
Approved as a device, not a drug, Plenity contains a plant-based gel that swells to fill 25% of a person鈥檚 stomach, to help people eat less. Results vary widely but are modest on average.
-
A Proposal to Import Drugs from Other Countries Creates an Unusual Alliance in the Senate
As a Senate committee considered legislation to reauthorize the FDA鈥檚 user fee program, Sens. Bernie Sanders and Rand Paul agreed on a proposed amendment related to importing drugs from Canada, the U.K., and other nations.
-
At a Bay Area 鈥楾est-to-Treat鈥 Site, Few Takers for Free Antivirals
In carrying out the federal covid-19 鈥渢est-to-treat鈥 initiative, California is targeting the uninsured by outfitting 138 testing sites with screenings for free antiviral drugs. But as of mid-June, fewer than 800 people had been prescribed the medicines. And two-thirds of those undergoing screenings are insured.
-
As Biden Fights Overdoses, Harm Reduction Groups Face Local Opposition
The Biden administration鈥檚 latest plan to address opioid overdose deaths includes $30 million for harm reduction measures, but many conservative states don鈥檛 allow them.
-
KHN鈥檚 鈥榃hat the Health?鈥: Taking a Shot at Gun Control
The U.S. House passed a package of bills seeking to keep some guns out of the hands of children and teenagers, but its fate in the Senate remains a big question mark. Meanwhile, the Federal Trade Commission takes on drug and hospital prices. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Cori Uccello of the American Academy of Actuaries about the most recent report from Medicare鈥檚 trustees board.
-
Lawmaker Takes on Insurance Companies and Gets Personal About His Health
State Sen. Scott Wiener opens up about a weeklong stint in the hospital last year and what it鈥檚 like to live with Crohn鈥檚 disease. The San Francisco Democrat is pushing a bill that would require insurance companies to cover certain medications while patients appeal denials.
-
Misinformation Clouds America鈥檚 Most Popular Emergency Contraception
At a moment when half of U.S. states stand poised to outlaw or sharply curtail abortion services, the nation鈥檚 most popular emergency contraception brand rests in the unlikely stewardship of two private equity firms.
By Sarah Varney -
California Wants to Slash Insulin Prices by Becoming a Drugmaker. Can It Succeed?
Gov. Gavin Newsom proposed spending $100 million to make insulin affordable to millions of people with diabetes under a new state generic drug label, CalRx. But state officials haven鈥檛 said how much the insulin will cost patients or how the state will deal with distribution and other challenges.
By Angela Hart -
Readers and Tweeters Go to the Mat on Abortion Rights and Perceived Wrongs
KHN gives readers a chance to comment on a recent batch of stories.
-
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?
By Arthur Allen and Sarah Jane Tribble -
Postcard From Minneapolis
Tribal Pharmacy Dispenses Free Meds and Fills Gaps for Native Americans in the City
The Mashkiki Waakaa鈥檌gan Pharmacy in downtown Minneapolis gives Native Americans an economical option for filling prescriptions while being sensitive to tribal traditions and expectations.
By Katherine Huggins and Julia Mueller -
Watch: Going Beyond the Script of 鈥楾he G Word鈥 and How Government Responds to Disease (Or Not)
KHN Editor-in-Chief Elisabeth Rosenthal joins comedian Adam Conover to discuss his new Netflix series, 鈥淭he G Word,鈥 which examines the federal government's role in Americans' lives, and how it plays out in the covid era.